Stockreport

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results [Yahoo! Finance]

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF Initiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer Presented compelling new data from Pha [Read more]